RESUMEN
An 11-month-old female, neutered domestic short-haired cat was presented for non-pruritic alopecia of the dorso-lumbar area which had appeared 1 month after a road accident. After the trauma, a fracture of the left hind limb was demonstrated without dermatological lesions on the dorso-lumbar area. One month later, hair loss was observed in this area. Four months later, clinical examination revealed dorso-lumbar alopecia. Histopathological findings included an absence of all adnexae, a mild fibroplasia and fibrosis without oriented collagen deposition, individual to coalescing pyogranulomas at the dermo-hypodermal junction and a moderately stenotic hypodermal artery. Clinical history, physical examination and histopathological findings were compatible with post-traumatic dorso-lumbar alopecia. Special features of this case include the location of the fracture and the more developed histopathological lesions with pyogranulomas at the dermo-hypodermal junction, the absence of hair follicles and a stenosing arteriopathy.
Asunto(s)
COVID-19/terapia , Pandemias , SARS-CoV-2 , Anticuerpos Antivirales/inmunología , Anticuerpos Antivirales/uso terapéutico , Seguridad de la Sangre , Infecciones de Transmisión Sanguínea/prevención & control , COVID-19/epidemiología , COVID-19/prevención & control , Vacunas contra la COVID-19/provisión & distribución , Países en Desarrollo , Predicción , Humanos , Inmunización Pasiva/ética , Inmunización Pasiva/normas , Cooperación Internacional , Control de Calidad , SARS-CoV-2/genética , SARS-CoV-2/inmunología , Resultado del Tratamiento , Sueroterapia para COVID-19Asunto(s)
Hemofilia A , Asia , Factor VIII , Humanos , Tolerancia Inmunológica , Estudios RetrospectivosRESUMEN
BACKGROUND AND OBJECTIVES: Recent clinical data suggested that platelet materials used in regenerative medicine exert anti-inflammatory effects. One must understand whether functionality varies among platelet preparations and also the role of the various protein compartments. MATERIALS AND METHODS: Platelet-poor-plasma (PPP), platelet lysate with cell debris (PL) or cell-free (CFPL), platelet gel releasate (PGR) and solvent/detergent-treated PL (SDPL) were prepared from four apheresis platelet donations. Protein profile was examined by SDS-PAGE, and growth factors and cytokines by ELISA, multiplexed Luminex assay and cytokine array. Anti-inflammatory activity was evaluated in RAW 264.7 mouse macrophages treated for 24 h with the blood fractions followed by 24 h of stimulation with 500 ng/ml lipopolysaccharides (LPS). Inflammatory marker nitric oxide (NO) was determined by colorimetry, tumour necrosis factor (TNF)-α by ELISA and inducible NO synthase (iNOS) and cyclooxygenase (COX)-2 by Western blotting. RESULTS: Proteins, growth factors and cytokines composition differed among preparations. Blood fractions alone did not stimulate inflammatory markers expression. Following LPS stimulus, NO and iNOS expressions were significantly inhibited (P < 0.001) by all blood fractions, but inhibition was more pronounced with SDPL. In addition, only SDPL inhibited TNF-α (P < 0.001) and COX-2 expressions. CONCLUSIONS: All the plasma and platelet fractions evaluated in this study exert an anti-inflammatory effect on macrophages, suggesting that both the plasma and platelet proteomes contribute to anti-inflammation. However, the extent and nature of the anti-inflammatory action vary among products. Further studies are needed to better understand the functionality of platelet biomaterials and optimize their clinical use.
Asunto(s)
Antiinflamatorios/farmacología , Materiales Biocompatibles/farmacología , Plaquetas/metabolismo , Macrófagos/efectos de los fármacos , Animales , Plaquetas/química , Línea Celular , Ciclooxigenasa 2/metabolismo , Citocinas/metabolismo , Dinoprostona/farmacología , Macrófagos/metabolismo , Ratones , Óxido Nítrico , Óxido Nítrico Sintasa/metabolismoRESUMEN
BACKGROUND AND OBJECTIVES: Instituto Clodomiro Picado has developed an immunoglobulin G (IgG) plasma fractionation process combining a polyethylene glycol/phosphate aqueous two-phase system (ATPS), caprylic acid precipitation and anion-exchange membrane chromatography. We evaluated the purity and in vitro thrombogenicity of such IgG, in line with current international requirements. MATERIALS AND METHODS: Contributions of the different production steps to reduce thrombogenicity were assessed at 0·2 l-scale, and then the methodology was scaled-up to a 10 l-scale and final products (n = 3) were analysed. Purity, immunoglobulin composition, and subclass distribution were determined by electrophoretic and immunochemical methods. The in vitro thrombogenic potential was determined by a thrombin generation assay (TGA) using a Technothrombin fluorogenic substrate. Prekallikrein activator (PKA), plasmin, factor Xa, thrombin and thrombin-like activities were assessed using S-2302, S-2251, S-2222, S-2238 and S-2288 chromogenic substrates, respectively, and FXI by an ELISA. RESULTS: The thrombogenicity markers were reduced mostly during the ATPS step and were found to segregate mostly into the discarded liquid upper phase. The caprylic acid precipitation eliminated the residual procoagulant activity. The IgG preparations made from the 10 l-batches contained 100% gamma proteins, low residual IgA and undetectable IgM. The IgG subclass distribution was not substantially affected by the process. TGA and amidolytic activities revealed an undetectable in vitro thrombogenic risk and the absence of proteolytic enzymes in the final product. CONCLUSIONS: Fractionating human plasma by an ATPS combined with caprylic acid and membrane chromatography resulted in an IgG preparation of high purity and free of a detectable in vitro thrombogenic risk.
Asunto(s)
Fraccionamiento Químico/métodos , Cromatografía/métodos , Inmunoglobulina G/aislamiento & purificación , Plasma/química , Caprilatos/química , Ensayo de Inmunoadsorción Enzimática , Factor XIIa/análisis , Humanos , Inmunoglobulina G/química , Oligopéptidos/química , Trombina/biosíntesisRESUMEN
Polyvalent immunoglobulin G (IgG) products obtained by fractionation of human plasma are used to treat a broad range of conditions, including immunodeficiency syndromes and autoimmune, inflammatory, and infectious diseases. Recent incidences of increased thromboembolic events (TEEs) associated with intravenous (IV) IgG (IVIG) led to recalls of some products and increased regulatory oversight of manufacturing processes in order to ensure that products are essentially free of procoagulant/thrombogenic plasma protein contaminants. Laboratory investigations have now identified activated factor XI (FXIa) as the likely causative agent of IVIG-related TEEs. Quantification of the thrombogenic potential is becoming a requirement made to fractionators (a) to validate the capacity of IVIG and subcutaneous IgG manufacturing processes to remove procoagulant contaminants and (b) to establish the safety of the final products. However, in the absence of a recommended test by the main regulatory authorities, several analytical approaches have been evaluated by fractionators, regulators, and university groups. This review focuses on the scientific rationale, merits, and applications of several analytical methods of quantifying the thrombogenic potential of IgG products and intermediates to meet the latest regulatory requirements.
Asunto(s)
Productos Biológicos/efectos adversos , Productos Biológicos/sangre , Inmunoglobulina G/efectos adversos , Inmunoglobulina G/sangre , Tromboembolia/etiología , Animales , Productos Biológicos/normas , Factores de Coagulación Sanguínea/efectos adversos , Factores de Coagulación Sanguínea/aislamiento & purificación , Química Farmacéutica , Contaminación de Medicamentos/prevención & control , Factor XIa/efectos adversos , Factor XIa/aislamiento & purificación , Humanos , Inmunoglobulinas Intravenosas/efectos adversos , Inmunoglobulinas Intravenosas/normas , Factores Inmunológicos/efectos adversos , Factores Inmunológicos/sangre , Medición de Riesgo , Tromboembolia/sangre , Tromboembolia/inmunologíaRESUMEN
von Willebrand disease (VWD) is frequently ignored as a cause of menorrhagia. We investigated Egyptian women complaining of heavy menstrual bleeding (HMB) and/or other bleeding symptoms to detect potential VWD cases. Seventy-five female patients complaining of HMB and/or bleeding symptoms and 38 age-matched healthy female controls went through a family history questionnaire, a physical examination and were evaluated for bleeding score, pictorial blood assessment chart (PBAC), complete blood count, serum ferritin, blood group, prothrombin time, activated partial thromboplastin time, factor VIII (FVIII) activity, von Willebrand factor (VWF) ristocetin cofactor (RCo) activity, antigen (Ag), and RCo/Ag ratio. Sixty-eight of 75 patients presented with HMB, out of which 46 had no organic pathology and 7 presented other bleeding symptoms. Six patients were diagnosed with VWD, three with HMB, two with other bleeding symptoms and one with family history of VWD. Two related VWD patients were diagnosed in the control group. There were significant differences in bleeding and PBAC scores, ferritin level, FVIII activity, VWF:RCo and VWF:Ag between VWD patients and controls. This study indicated a high prevalence of VWD among patients with HMB without organic pathology (6.5%) and demonstrated the sensitivity of diagnostic parameters of VWD patients in an outreach campaign. The inexpensive bleeding and PBAC scoring systems are valuable to exclude cases without objective bleeding symptoms. Raising gynaecologists awareness about hereditary bleeding disorders is important to ensure a proper diagnosis and possible referral of these patients. Management of these patients with comprehensive medical care services under a multidisciplinary team would be ideal.
Asunto(s)
Hemorragia/diagnóstico , Menorragia/diagnóstico , Enfermedades de von Willebrand/diagnóstico , Adulto , Pruebas de Coagulación Sanguínea , Estudios de Casos y Controles , Diagnóstico Diferencial , Egipto , Femenino , Hemorragia/etiología , Humanos , Menorragia/etiología , Persona de Mediana Edad , Encuestas y Cuestionarios , Adulto Joven , Enfermedades de von Willebrand/complicacionesRESUMEN
BACKGROUND AND OBJECTIVES: A minipool solvent/detergent (S/D; 1% TnBP/1% Triton X-45; 31°C) process was developed for viral inactivation of plasma and cryoprecipitate used for transfusion. The goal of this study was to determine the rate and extent of inactivation of dengue virus (DENV) during this process. MATERIALS AND METHODS: DENV-1 was propagated using C6/36 mosquito cells to an infectivity titre close to 9 log and spiked (10% v/v) into individual plasma and cryoprecipitate samples from two distinct donors. Samples were taken right after spiking and during viral inactivation treatment by 1% TnBP-1% Triton X-45 at 31°C. DENV-1 infectivity was assessed on Vero E6 cells by a focus-forming assay (FFA). Culture medium and complement-inactivated plasma were used as experimental controls. Experiments were done in duplicate. RESULTS: DENV-1 infectivity was 7·5 log in spiked plasma and 7·1 and 7·3 log in spiked cryoprecipitate. There was no loss of DENV-1 infectivity in the spiked materials, nor in the controls not subjected to S/D treatment. No infectivity was found in plasma and cryoprecipitate subjected to S/D treatment at the first time-point evaluated (10 min). CONCLUSION: DENV-1 was strongly inactivated in plasma and cryoprecipitate, respectively, within 10 min of 1% TnBP/1% Triton X-45 treatment at 31°C. These data provide a reassurance of the safety of such S/D-treated plasma and cryoprecipitate with regard to the risk of transmission of all DENV serotypes and other flaviviruses.
Asunto(s)
Virus del Dengue/efectos de los fármacos , Octoxinol/farmacología , Organofosfatos/farmacología , Plasma/efectos de los fármacos , Inactivación de Virus , Animales , Conservación de la Sangre , Seguridad de la Sangre , Transfusión Sanguínea , Chlorocebus aethiops , Proteínas del Sistema Complemento , Culicidae , Dengue/prevención & control , Detergentes , Factor VIII/química , Fibrinógeno/química , Humanos , Solventes/química , Factores de Tiempo , Células VeroRESUMEN
BACKGROUND: A solvent/detergent (S/D) treatment in a medical device has been developed for pathogen reduction of plasma for transfusion. Impact of S/D on bacterial growth and on the capacity of complement to kill bacteria has been investigated in this study. STUDY DESIGN AND METHODS: A pool of apheresis plasma from four donors was spiked with eight transfusion-relevant bacteria. Plasma was treated with 1% tri(n-butyl) phosphate and 1% Triton X-45 at 31°C for 90 min and then extracted by oil at 31°C for 70 min. Decomplemented plasma and Phosphate Buffer Saline were used as controls. Bacterial count was determined in samples taken immediately after spiking, or after S/D and oil treatment. Similar experiments were conducted using three individual recovered plasma donations. Bacteria growth inhibition tests were performed using discs soaked with plasma samples whether containing the S/D agents or not. RESULTS: The mean reduction factors of Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae due to complement during S/D treatment were >8·75, 4·71, and 4·18 log in pooled plasma and >7·42, 2·24 and >6·08 log in individual plasmas, respectively. Bacillus cereus and Bacillus subtilis were inactivated by S/D (>7·04 and 1·60 log in pooled, and >6·06 and 2·39 in individual plasmas, respectively). Staphylococcus aureus, Staphylococcus epidermidis and Enterobacter cloacae did not multiply during S/D treatment of plasma. Growth inhibition tests revealed an inhibition of three gram-negative bacteria by complement and all gram-positive by S/D. CONCLUSION: The S/D treatment of plasma does not alter the bactericidal activity of complement, and inactivates some gram-positive bacteria.
Asunto(s)
Bacterias/efectos de los fármacos , Detergentes/farmacología , Plasma/efectos de los fármacos , Reacción a la Transfusión , Bacterias/crecimiento & desarrollo , Transfusión Sanguínea/normas , Proteínas del Sistema Complemento , Bacterias Gramnegativas , Humanos , Plasma/microbiología , Solventes/químicaRESUMEN
BACKGROUND AND OBJECTIVES: TGF-ß1 exerts important physiological functions in osteogenesis and chondrogenesis and may be of therapeutic interest. The aim of this work was to develop a scalable purification process of TGF-ß1 from virally inactivated human platelets. STUDY DESIGN AND METHODS: Apheresis platelet concentrates (N=12) were solvent/detergent (S/D) treated (1% TnBP/1% Triton X-45; 31°C) and the resulting platelet lysates were clarified by oil extraction and centrifugation, then chromatographed on an anion-exchange DEAE-Sepharose Fast-Flow column equilibrated in a PBS buffer, pH 7.5. The column was washed to eliminate unbound proteins and the S/D agents. Bound proteins were eluted using a 1 M NaCl-PBS buffer pH 7.5 (DEAE-eluate). The content in TGF-ß1, PDGF-AB, VEGF, IGF-1, EGF, and b-FGF was measured by ELISA. Proteins, lipids, and S/D agents were assessed. Protein profile was determined by SDS-PAGE under reduced or non-reduced conditions. RESULTS: Most proteins, including albumin and immunoglobulins G, A, and M did not bind to the DEAE column as evidenced also by SDS-PAGE. Essentially all PDGF, VEGF, and IGF were in the breakthrough. The DEAE-eluate contained close to 60% of the TGF-ß1 at a mean concentration of about 102 ng/ml, whereas EGF, b-FGF were at about 0.72 and 0.18 ng/ml, respectively. The content in TnBP and Triton X-45 was <2 ppm. CONCLUSION: A fraction enriched in TGF-ß1 can be prepared from virally inactivated human platelet lysates using an easily scale process. Its interest in regenerative medicine and cell therapy will be evaluated in further studies.
Asunto(s)
Plaquetas/química , Factor de Crecimiento Transformador beta1/química , Factor de Crecimiento Transformador beta1/aislamiento & purificación , Inactivación de Virus , Plaquetas/virología , Cromatografía por Intercambio Iónico/métodos , Citocinas/química , Humanos , Inmunoglobulinas/química , Octoxinol/químicaRESUMEN
Eighteen cryoprecipitate minipools, each made of 30 units of low volume, concentrated cryoprecipitate, have been treated by solvent-detergent and filtration (S/D-F) in a single-use CE-marked bag system. The S/D-F cryoprecipitate contained a mean of 10.5 IU mL⻹ factor VIII (FVIII), 17 mg mL⻹ clottable fibrinogen, and >10 IU mL⻹ von Willebrand factor ristocetin co-factor, and anti-A and anti-B isoagglutinins were undetectable. The products have been infused in 11 severe (FVIII <1%) haemophilia A patients (mean age: 17.4 years; mean weight: 57.6 kg) at a dose close to 40 IU kg⻹. Patients were hospitalized for at least 36 h to determine FVIII recovery, half-life and clearance. They were also closely monitored for possible adverse events. None of the infused patients demonstrated reactions or adverse events even though they did not receive anti-allergic drugs or corticosteroids prior to infusion. The mean recovery of FVIII 10 min postinfusion was 69.7%. Mean FVIII half-life was 14.2 h and clearance was 2.6 mL h⻹ kg⻹. All patients had a bleeding-free interval of 8-10 days postS/D-F cryoprecipitate infusion. The data show that S/D-F cryoprecipitate FVIII presents a normal pharmacokinetics profile, and support that it could be safely used for the control of acute and chronic bleeding episodes in haemophilia A patients.
Asunto(s)
Factor VIII/farmacocinética , Fibrinógeno/farmacocinética , Hemofilia A/metabolismo , Adolescente , Adulto , Conservación de la Sangre/métodos , Niño , Factor VIII/química , Fibrinógeno/química , Semivida , Hemofilia A/tratamiento farmacológico , Humanos , Tasa de Depuración Metabólica , Solventes , Adulto JovenRESUMEN
For almost 50 years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins--such as coagulation factors, anticoagulants, immunoglobulins, and albumin--essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20 years, the application of recombinant technologies to mammalian cell cultures has made possible--although with some limitations in productivity, costs, and immunogenic risks--to produce and commercialize complex plasma glycoproteins for human therapeutic applications and has opened the way to the development of new molecular entities. Today, the advanced exploration of alternative cell lines and enhanced cell culture systems, as well as the development of alternative expression technologies, such as transgenic animals, is opening a new era in the production of the full range of recombinant plasma protein therapeutics. In this review, we examine the achievements and ongoing challenges of the recombinant DNA technology as a platform for the production of plasma proteins and the advantages and limitations of such products compared to fractionated plasma proteins.
Asunto(s)
Proteínas Sanguíneas/biosíntesis , Proteínas Sanguíneas/genética , Animales , Animales Modificados Genéticamente , Anticuerpos Monoclonales/biosíntesis , Anticuerpos Monoclonales/genética , Anticoagulantes/metabolismo , Factores de Coagulación Sanguínea/biosíntesis , Factores de Coagulación Sanguínea/genética , Técnicas de Cultivo de Célula , ADN Recombinante/genética , Expresión Génica , Humanos , Inmunoglobulina G/biosíntesis , Inmunoglobulina G/genética , Plantas Modificadas Genéticamente , Inhibidores de Proteasas/metabolismo , Ingeniería de Proteínas , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/genéticaRESUMEN
Solvent-detergent (S/D) viral inactivation was recently adapted to the treatment of single plasma donations and cryoprecipitate minipools. We present here a new process and a new bag system where the S/D reagents are removed by filtration and the final products subjected to bacterial (0.2 microm) filtration. Recovered and apheresis plasma for transfusion (FFP) and cryoprecipitate minipools (400 +/- 20 mL) were subjected to double-stage S/D viral inactivation, followed by one oil extraction and a filtration on a S/D and phthalate [di(2-ethylhexyl) phthalate (DEHP)] adsorption device and a 0.2 microm filter. The initial and the final products were compared for visual appearance, blood cell count and cell markers, proteins functional activity, von Willebrand factor (VWF) multimers and protein profile by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Tri (n-butyl) phosphate (TnBP) was quantified by gas chromatography and Triton X-45 and DEHP by high-performance-liquid chromatography (HPLC). General safety tests were by 6.5 mL/kg intravenous injection in rats. The treated plasmas and cryoprecipitates were very clear and the protein content and functionality, VWF multimers and SDS-PAGE profiles were well preserved. TnBP and Triton X-45 were < 1 and <25 ppm, respectively, and DEHP (about 5 ppm) was less than it was in the starting materials. Blood cell counts and CD45, CD61 and glycophorin A markers were negative. There was no enhanced toxicity in rats. Thus, plasma and cryoprecipitate can be S/D-treated in this new CE-marked disposable integral processing system under conditions preserving protein function and integrity, removing blood cells, S/D agents and DEHP, and ensuring bacterial sterility. This process may offer one additional option to blood establishments for the production of virally inactivated plasma components.
Asunto(s)
Eliminación de Componentes Sanguíneos/métodos , Conservación de la Sangre/instrumentación , Criopreservación/instrumentación , Factor VIII , Fibrinógeno , Plasma , Inactivación de Virus , Animales , Recuento de Células Sanguíneas , Electroforesis de las Proteínas Sanguíneas , Proteínas Sanguíneas/análisis , Cromatografía Líquida de Alta Presión , Detergentes/análisis , Dietilhexil Ftalato/análisis , Femenino , Filtración , Humanos , Masculino , Octoxinol/análisis , Organofosfatos/análisis , Ratas , Ratas Sprague-Dawley , Solventes/análisis , Desintoxicación por SorciónRESUMEN
Intravenous immunoglobulin G (IVIG) is now the leading product obtained by fractionation of human plasma. It is the standard replacement therapy in primary and acquired humoral deficiency, and is also used for immunomodulatory therapy in various autoimmune disorders and transplantation. Over the last 30 years, the production processes of IVIG have evolved dramatically, gradually resulting in the development of intact IgG preparations safe to administer intravenously, with normal half-life and effector functions, prepared at increased yield, and exhibiting higher pathogen safety. This article reviews the developments that have led to modern IVIG preparations, the current methods used for plasma collection and fractionation, the safety measures implemented to minimize the risks of pathogen transmission and the major quality control tests that are available for product development and as part of mandatory batch release procedures.
Asunto(s)
Inmunoglobulinas Intravenosas/normas , Fraccionamiento Químico , Humanos , Inmunoglobulinas Intravenosas/aislamiento & purificación , Inmunoglobulinas Intravenosas/uso terapéutico , Garantía de la Calidad de Atención de Salud , Control de Calidad , Inactivación de VirusRESUMEN
BACKGROUND: Human platelet growth factors (HPGF) are essential for tissue regeneration and may replace fetal bovine serum (FBS) in cell therapy. No method for the manufacture of standardized virally inactivated HPGF has been developed yet. STUDY DESIGN AND METHODS: Platelet concentrates (PC) were subjected to solvent/detergent (S/D) treatment (1% TnBP/1% Triton X-45), oil extraction, hydrophobic interaction chromatography and sterile filtration. Platelet-derived growth factor (PDGF)-AB, -BB and -AA, transforming growth factor-beta1 (TGF-beta1), epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1) and vascular endothelium growth factor (VEGF) were measured by ELISA. Composition in proteins and lipids was determined, protein profiles were obtained by SDS-PAGE, and TnBP and Triton X-45 were assessed by gas chromatography and high-performance liquid chromatography, respectively. Cell growth promoting activity of HPGF was evaluated by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay using human embryonic kidney (HEK293A) fibroblast and Statens Seruminstitute rabbit corneal (SIRC) epithelial cell lines. RESULTS: The GF preparation contained a mean of 16.66, 2.04, 1.53, 72.19, 0.33, 48.59 and 0.44 ng/ml of PDGF-AB, -BB, -AA, TGF-beta1, EGF, IGF-1 and VEGF, respectively. The protein profile was typical of platelet releasates and had less than 2 p.p.m. of residual S/D agents. MTS assay of HEK293A and SIRC cultures showed that the GF preparation at 10% and 0.1% (v/v), respectively, could successfully replace 10% FBS for cell proliferation. Cell-stimulating activity of HPGF on HEK293A was over twice that of PC releasates. CONCLUSION: STANDARDIZED and functional virally inactivated HPGF can be prepared from human PC for possible applications in cell therapy and regenerative medicine.
Asunto(s)
Plaquetas/química , Péptidos y Proteínas de Señalización Intercelular/aislamiento & purificación , Animales , Línea Celular , Proliferación Celular/efectos de los fármacos , Trasplante de Células/métodos , Fraccionamiento Químico/métodos , Ensayo de Inmunoadsorción Enzimática , Humanos , Péptidos y Proteínas de Señalización Intercelular/farmacología , Conejos , Medicina Regenerativa/métodosRESUMEN
Non-virally inactivated plasma, cryoprecipitate and cryoprecipitate-poor plasma, prepared by blood establishments, are still used in many countries in the world, in both the developing world and industrialized countries, for the treatment of various hematological disorders. In the absence of viral inactivation treatment, these fractions may be involved, in spite of increasingly sensitive viral detection methods, into the transmission of plasma-borne viruses, most critically HIV and Hepatitis B (HBV) or C (HCV). We have adapted the well-established industrial solvent-detergent (SD) viral inactivation treatment to allow its application in a small scale using a single-use plastic bag system. The procedure can be used by blood establishments, without the need to build an industrial-scale manufacturing facility. Results show a good recovery of the functional activity of plasma proteins, including coagulation factors (such as factor VIII and coagulable fibrinogen) and/or protease inhibitors (such as alpha 2-antiplasmin). Viral validation studies revealed reduction factors greater than 4.17, greater than 4.73 and greater than 4.72 for HIV, BVDV and PRV, respectively, within a few minutes of treatment. A single-use SD treatment and SD-elimination system is currently under development to allow standardized use of the procedure by blood establishments or national or regional service centers.